CERENOME, INC.
For the period ended Mar 31, 2025. Filed May 30, 2025.
View on SEC.govAbout this filing
A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.
Mar 31, 2025 · Filed May 30, 2025
CNSY$0.68+19.0%Stored close · as of Nov 10, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Condensed Consolidated Statements of Cash Flows
(In thousands)
| For the Three Months Ended March 31, | ||
|---|---|---|
| 2025 | 2024 | |
| Cash flows used in operating activities: | ||
| Net loss | $(17,401) | $(3,261) |
| Adjustments to reconcile net loss to net cash used in operating activities: | ||
| Depreciation and amortization | 146 | 155 |
| Amortization of deferred financing costs and debt discount | — | 16 |
| Share-based compensation expense | 148 | 146 |
| Noncash financing expenses | 3,211 | — |
| Change in fair value of derivative instruments | 9,143 | — |
| Accretion of discount on short-term investments | — | 1 |
| Reduction in the carrying amount of operating lease right-of-use assets | 35 | 31 |
| Loss on disposal of property and equipment | (16) | — |
| Increases (decreases) in cash caused by changes in operating assets and liabilities: | ||
| Grant receivable | 571 | — |
| Other current assets | 74 | 150 |
| Accounts payable and accrued expenses | (2,418) | (43) |
| Change in operating lease liabilities | (35) | (31) |
| Deferred grant liability | 370 | (1,677) |
| Net cash used in operating activities | (6,172) | (4,513) |
| Cash flows used in investing activities: | ||
| Purchases of property and equipment | (3) | (40) |
| Proceeds from sale of property and equipment | 30 | — |
| Redemption of short-term investments | 3,531 | (324) |
| Net cash provided by (used in) investing activities | 3,558 | (364) |
| Cash flows used in/provided by financing activities: | ||
| Principal payments of term loan obligation | — | (402) |
| Repayment of line of credit facility | (3,292) | — |
| Repayment of notes payable | (3,703) | — |
| Issuance of notes payable and warrants | 3,738 | |
| Proceeds from exercise of warrants | 882 | |
| Purchase of treasury stock | — | (374) |
| Proceeds from sale of common stock, prefunded warrants and warrants, net | 14,780 | — |
| Net cash provided by (used in) financing activities | 12,405 | (776) |
| Net increase (decrease) in cash and cash equivalents | 9,791 | (5,653) |
| Cash and cash equivalents at beginning of period | 76 | 8,554 |
| Cash and cash equivalents at end of period | $9,867 | $2,901 |
| Supplemental disclosure of cash flows information: | ||
| Cash paid during period for: | ||
| Interest | $539 | $23 |
| Supplemental schedule of non-cash investing and financing activities: | ||
| Exchange of warrants for notes payable | $3,694 | $— |
| Redemption of notes by issuance of common stock, prefunded warrants and warrants | $3,512 | $— |
| Unpaid offering cost | $202 | $141 |
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.